FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:162-167 July 15, 1993 Number 3 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Clozapine is an atypical antipsychotic agent that is more effective than standard neuroleptic drugs in the treatment of patients with refractory schizophrenia. Unlike classic neuroleptic agents, clozapine is not associated with the development of acute extrapyramidal symptoms or tardive dyskinesia. The main factor limiting its use is the risk of potentially fatal agranulocytosis, estimated to occur in 1 to 2 percent of treated patients. After clozapine was approved by the Food and Drug Administration, it became available for marketing in the United States in February 1990 only as part of a special surveillance system (the Clozaril Patient Management System, or CPMS), in which a weekly white-cell count was required for the patient to receive a supply of the drug.

Methods We evaluated the CPMS data for February 1990 through April 1991 by survival analysis to determine the incidence of agranulocytosis and the effects of potential risk factors such as age and sex. Data were available for 11,555 patients who received clozapine during the period after marketing began.

Results Agranulocytosis developed in 73 patients, resulting in death from infectious complications in 2 patients. Episodes of agranulocytosis occurred in 61 patients within three months after they began treatment. The cumulative incidence of this side effect was 0.80 percent (95 percent confidence interval, 0.61 to 0.99) at 1 year and 0.91 percent (95 percent confidence interval, 0.62 to 1.20) at 1 1/2 years. The risk of agranulocytosis increased with age and was higher among women.

Conclusions The occurrence of agranulocytosis is a substantial hazard of the administration of clozapine, but this hazard can be reduced by monitoring the white-cell count. The increasing risk of agranulocytosis with age and the reduced incidence after the first six months of treatment provide additional guidelines for the prescription and monitoring of clozapine treatment in the future.

Source Information

From the Department of Psychiatry, Hillside Hospital, Division of Long Island Jewish Medical Center, Glen Oaks, N.Y. (J.M.J.A., J.A.L., A.Z.S.); the Department of Psychiatry, Albert Einstein College of Medicine, Bronx, N.Y. (J.M.J.A., J.A.L., A.Z.S.); and Sandoz Pharmaceuticals, East Hanover, N.J. (J.L.S., J.A.S.).

Address reprint requests to Dr. Alvir at Hillside Hospital, Long Island Jewish Medical Ctr., 75-59 263rd St., Glen Oaks, NY 11004.

Full Text of this Article

This article has been cited by other articles:

• Kayir, H., Uzbay, T. (2008). Effects of Clozapine on Ethanol Withdrawal Syndrome in Rats. Alcohol Alcohol 43: 619-625 [Abstract] [Full Text]  
• Takakusa, H., Masumoto, H., Mitsuru, A., Okazaki, O., Sudo, K. (2008). Markers of Electrophilic Stress Caused by Chemically Reactive Metabolites in Human Hepatocytes. Drug Metab. Dispos. 36: 816-823 [Abstract] [Full Text]  
• Seeman, M. V. (2008). Secondary Effects of Antipsychotics: Women at Greater Risk Than Men. Schizophr Bull 0: sbn023v1-sbn023 [Abstract] [Full Text]  
• Kutscher, E. C., Robbins, G. P., Kennedy, W. K., Zebb, K., Stanley, M., Carnahan, R. M. (2007). Clozapine-induced leukopenia successfully treated with lithium. Am J Health Syst Pharm 64: 2027-2031 [Abstract] [Full Text]  
• Downs, J., Zinkler, M. (2007). Clozapine: national review of postcode prescribing. Psychiatr. Bull. 31: 384-387 [Abstract] [Full Text]  
• Kelly, D. L., Kreyenbuhl, J., Dixon, L., Love, R. C., Medoff, D., Conley, R. R. (2007). Clozapine Underutilization and Discontinuation in African Americans Due to Leucopenia. Schizophr Bull 33: 1221-1224 [Abstract] [Full Text]  
• Evans, J. D., Evans, E. W. (2007). Review of eight restricted-access programs and potential implications for pharmacy. Am J Health Syst Pharm 64: 1302-1310 [Full Text]  
• Gottlieb, S. (2007). Drug Safety Proposals And The Intrusion Of Federal Regulation Into Patient Freedom And Medical Practice. Health Aff (Millwood) 26: 664-677 [Abstract] [Full Text]  
• Noel, J. M. (2007). ASHP Therapeutic Position Statement on the Use of Second-Generation Antipsychotic Medications in the Treatment of Adults with Psychotic Disorders. Am J Health Syst Pharm 64: 863-876 [Full Text]  
• Schulte, P. F. (2006). Risk of Clozapine-Associated Agranulocytosis and Mandatory White Blood Cell Monitoring. The Annals of Pharmacotherapy 40: 683-688 [Abstract] [Full Text]  
• Rajagopal, S (2005). Clozapine, agranulocytosis, and benign ethnic neutropenia. Postgrad. Med. J. 81: 545-546 [Full Text]  
• SEDKY, K., SHAUGHNESSY, R., HUGHES, T., LIPPMANN, S. (2005). Clozapine-Induced Agranulocytosis After 11 Years of Treatment. Am. J. Psychiatry 162: 814-814 [Full Text]  
• Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., MacIntyre, J. C. II, Pappadopulos, E., Greenhill, L., Schooler, N., Van Orden, K., Jensen, P. S. (2004). Treatment Recommendations for the Use of Antipsychotics for Aggressive Youth (TRAAY), Part I: A Review. Focus 2: 596-607 [Abstract] [Full Text]  
• Woodall, A. A., Menkes, D. B., Trevelyan, T. R., Lanceley, C. P. (2004). A study of clozapine and long-term hospitalisation rates. Psychiatr. Bull. 28: 285-288 [Abstract] [Full Text]  
• Pollak, P, Tison, F, Rascol, O, Destee, A, Pere, J J, Senard, J M, Durif, F, Bourdeix, I (2004). Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J. Neurol. Neurosurg. Psychiatry 75: 689-695 [Abstract] [Full Text]  
• Amabile, C. M., Spencer, A. P. (2004). Keeping Your Patient With Heart Failure Safe: A Review of Potentially Dangerous Medications. Arch Intern Med 164: 709-720 [Full Text]  
• Pirmohamed, M., Ferner, R. E (2003). Monitoring drug treatment. BMJ 327: 1179-1181 [Full Text]  
• Tanner, M A, Culling, W (2003). Clozapine associated dilated cardiomyopathy. Postgrad. Med. J. 79: 412-413 [Abstract] [Full Text]  
• Kuno, E., Rothbard, A. B. (2002). Racial Disparities in Antipsychotic Prescription Patterns for Patients With Schizophrenia. Am. J. Psychiatry 159: 567-572 [Abstract] [Full Text]  
• Wooltorton, E. (2002). Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity. CMAJ 166: 1185-1186 [Full Text]  
• Geddes, J. (2002). Prevention of Relapse in Schizophrenia. NEJM 346: 56-58 [Full Text]  
• Graham, D. J., Drinkard, C. R., Shatin, D., Tsong, Y., Burgess, M. J. (2001). Liver Enzyme Monitoring in Patients Treated With Troglitazone. JAMA 286: 831-833 [Abstract] [Full Text]  
• Sernyak, M. J., Desai, R., Stolar, M., Rosenheck, R. (2001). Impact of Clozapine on Completed Suicide. Am. J. Psychiatry 158: 931-937 [Abstract] [Full Text]  
• Kho, K. H., Nielsen, O. (2001). Clozapine-induced nocturnal enuresis: diagnostic and treatment issues. Psychiatr. Bull. 25: 232-233 [Abstract] [Full Text]  
• Hundertmark, J., Campbell, P. (2001). Reintroduction of clozapine after diagnosis of lymphoma. Br. J. Psychiatry 178 : 576-576 [Full Text]  
• Beelen, A P, Yeo, K-T., Lewis, L D (2001). Asymptomatic QTc prolongation associated with quetiapine fumarate overdose in a patient being treated with risperidone. Hum Exp Toxicol 20: 215-219 [Abstract]  
• Henderson, D. C., Borba, C. P. (2001). Trimethoprim-Sulfamethoxazole and Clozapine. Psychiatr. Serv. 52: 111-112 [Full Text]  
• Dettling, M., Cascorbi, I., Roots, I., Mueller-Oerlinghausen, B. (2001). Genetic Determinants of Clozapine-Induced Agranulocytosis: Recent Results of HLA Subtyping in a Non-Jewish Caucasian Sample. Arch Gen Psychiatry 58: 93-94 [Full Text]  
• Lieberman, J. A., Golden, R., Stroup, S., McEvoy, J. (2000). Drugs of the Psychopharmacological Revolution in Clinical Psychiatry. Psychiatr. Serv. 51: 1254-1258 [Full Text]  
• Street, J. S., Clark, W. S., Gannon, K. S., Cummings, J. L., Bymaster, F. P., Tamura, R. N., Mitan, S. J., Kadam, D. L., Sanger, T. M., Feldman, P. D., Tollefson, G. D., Breier, A., for the HGEU Study Group, (2000). Olanzapine Treatment of Psychotic and Behavioral Symptoms in Patients With Alzheimer Disease in Nursing Care Facilities: A Double-blind, Randomized, Placebo-Controlled Trial. Arch Gen Psychiatry 57: 968-976 [Abstract] [Full Text]  
• Committee on Drugs, (2000). Use of Psychoactive Medication During Pregnancy and Possible Effects on the Fetus and Newborn. Pediatrics 105: 880-887 [Abstract] [Full Text]  
• Adams, C., Wilson, P., Gilbody, S., Bagnall, A.-M., Lewis, R. (2000). Drug treatments for schizophrenia. Qual Saf Health Care 9: 73-79 [Full Text]  
• Lai, W. G., Gardner, I., Zahid, N., Uetrecht, J. P. (2000). Bioactivation and Covalent Binding of Hydroxyfluperlapine in Human Neutrophils: Implications for Fluperlapine-Induced Agranulocytosis. Drug Metab. Dispos. 28: 255-263 [Abstract] [Full Text]  
• Wahlbeck, K., Cheine, M., Essali, A., Adams, C. (1999). Evidence of Clozapine's Effectiveness in Schizophrenia: A Systematic Review and Meta-Analysis of Randomized Trials. Am. J. Psychiatry 156: 990-999 [Abstract] [Full Text]  
• The Parkinson Study Group, (1999). Low-Dose Clozapine for the Treatment of Drug-Induced Psychosis in Parkinson's Disease. NEJM 340: 757-763 [Abstract] [Full Text]  
• Gupta, S., Noor-Khan, N., Frank, B. (1998). Agranulocytosis in a Second Clozapine Trial. Psychiatr. Serv. 49: 1094-1094 [Full Text]  
• Gardner, I., Zahid, N., MacCrimmon, D., Uetrecht, J. P. (1998). A Comparison of the Oxidation of Clozapine and Olanzapine to Reactive Metabolites and the Toxicity of these Metabolites to Human Leukocytes. Mol. Pharmacol. 53: 991-998 [Abstract] [Full Text]  
• Gardner, I., Leeder, J. S., Chin, T., Zahid, N., Uetrecht, J. P. (1998). A Comparison of the Covalent Binding of Clozapine and Olanzapine to Human Neutrophils In Vitro and In Vivo. Mol. Pharmacol. 53: 999-1008 [Abstract] [Full Text]  
• King, D. J., Wager, E. (1998). Haematological safety of antipsychotic drugs. J Psychopharmacol 12: 283-288 [Abstract]  
• Rosenheck, R., Cramer, J., Xu, W., Thomas, J., Henderson, W., Frisman, L., Fye, C., Charney, D., The Department of Veterans Affairs Cooperative Stu, (1997). A Comparison of Clozapine and Haloperidol in Hospitalized Patients with Refractory Schizophrenia. NEJM 337: 809-815 [Abstract] [Full Text]  
• Guith, D. M. (1996). Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy. Journal of Pharmacy Practice 9: 118-129 [Abstract]  
• Johnstone, E. C, Sandler, R. (1996). Treatment resistance in schizophrenia. BMJ 312: 325-326 [Full Text]  
• Kane, J. M. (1996). Schizophrenia. NEJM 334: 34-42 [Full Text]  
• Gerson, S. L. (1993). Clozapine -- Deciphering the Risks. NEJM 329: 204-205 [Full Text]